Global SJS TEN Treatment Market - Industry Trends and Forecast to 2030

Global SJS TEN Treatment Market - Industry Trends and Forecast to 2030

The global SJS/TEN treatment market is expected to reach USD 12,586.71 million by 2030 from USD 7,100.00 million in 2022, growing at a CAGR of 7.6% during the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.
Market Segmentation:
Global SJS/TEN Treatment Market, By Treatment (Medications, Support Care, Hospitalization, Isolation, Ointments, and Others), Diagnosis (Physical Exam, Skin Biopsy, Medical History, Blood Test, Cultures, and Others), Cause (Specific Treatment, Infection, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Drug Type (Branded and Generic), Therapy Area (Combination Therapy and Monotherapy), Patient Type (Geriatric, Adult, and Pediatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center, Homecare Setting, and Others), Distribution Channel (Retail Pharmacies, Direct Tender, and Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Russia, Spain, Netherlands, Denmark, Switzerland, Sweden, Poland, Norway, Finland, Belgium, Turkey, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Indonesia, Philippines, Thailand, Malaysia, Singapore, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, South Africa, Bahrain, Kuwait, Oman, Qatar, U.A.E., Egypt, Israel, and Rest of Middle East and Africa) - Industry Trends & Forecast to 2030
Overview of Global SJS/TEN Treatment Market Dynamics:


Driver
• Increasing awareness about the rare disease SJS/TEN

Restrain

• High cost associated with SJS/TEN treatment

Opportunity

• Increasing research and development activities for SJS/TEN treatment


Market Players:

Some of the key market players operating in the global SJS/TEN treatment market are listed below:

• 3M
• Cardinal Health
• BD
• Smith + Nephew
• Novartis AG
• Amneal Pharmaceuticals LLC.
• Amgen Inc.
• Pfizer Inc.
• Colgate-Palmolive Company
• Merck & Co., Inc.
• Mölnlycke Health Care AB.
• Xttrium Laboratories
• Schülke & Mayr GmbH
• ICPA Health Products Ltd
• Purdue Pharma L.P.
• eugia (Subsidiary of Aurobindo Pharma)
• AdvaCare Pharma

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.